FBT:NYE-First Trust NYSE Arca Biotechnology Index Fund (USD)

ETF | Health |

Last Closing

USD 170.04

Change

-5.56 (-3.17)%

Market Cap

N/A

Volume

0.02M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-14 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-2.31 (-1.57%)

USD 40.46B
FHLC Fidelity® MSCI Health Care In..

-1.17 (-1.67%)

USD 2.91B
FXH First Trust Health Care AlphaD..

-2.16 (-1.94%)

USD 1.19B
XHE SPDR® S&P Health Care Equipme..

-1.78 (-1.96%)

USD 0.22B
IDNA iShares Genomics Immunology an..

-0.66 (-2.70%)

USD 0.15B
SBIO ALPS Medical Breakthroughs ETF

-1.18 (-2.93%)

USD 0.13B
XHS SPDR® S&P Health Care Service..

-2.68 (-2.80%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.79 (-2.68%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

-1.78 (-2.73%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.93 (-3.17%)

USD 0.01B

ETFs Containing FBT

FHM:CA 0.00 % 0.78 %

N/A

N/A
FBT:CA First Trust NYSE Arca Bio.. 0.00 % 0.00 %

+0.21 (+0.69%)

CAD 1.83M

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.58% 62% D 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.58% 62% D 42% F
Trailing 12 Months  
Capital Gain 22.78% 62% D 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.78% 62% D 59% D-
Trailing 5 Years  
Capital Gain 23.94% 38% F 60% D-
Dividend Return 1.61% 39% F 4% F
Total Return 25.56% 33% F 47% F
Average Annual (5 Year Horizon)  
Capital Gain 1.20% 33% F 38% F
Dividend Return 1.53% 33% F 30% F
Total Return 0.33% 42% F 9% A-
Risk Return Profile  
Volatility (Standard Deviation) 12.06% 95% A 74% C
Risk Adjusted Return 12.71% 38% F 31% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.